Artiva Biotherapeutics (ARTV) Operating Leases (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Operating Leases data on file, last reported at $7.2 million in Q1 2026.

• On a quarterly basis, Operating Leases fell 29.59% year-over-year to $7.2 million in Q1 2026; TTM through Mar 2026 was $7.2 million, a 29.59% decrease from a year earlier, with the FY2025 full-year figure at $7.9 million, down 25.42% from the prior year.
• Operating Leases for Q1 2026 stood at $7.2 million, down from $7.9 million in the prior quarter.
• Over the last five years, Operating Leases for ARTV reached as high as $15.5 million in Q2 2024 and fell as low as $7.2 million in Q1 2026.
• Historically, Operating Leases has averaged $10.5 million across 4 years, with a median of $10.3 million in 2025.
• Across the five-year window, Operating Leases dropped 20.62% in 2024 and slumped 38.35% in 2025, its largest moves.
• Year by year, Operating Leases stood at $13.3 million in 2023, then slipped by 20.62% to $10.6 million in 2024, then declined by 25.42% to $7.9 million in 2025, then slipped by 8.31% to $7.2 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $7.2 million in Q1 2026, $7.9 million in Q4 2025, and $8.5 million in Q3 2025.